NUVAXOVID
The FDA has provided updated indication details for NUVAXOVID, a vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The guidance specifies approval for individuals aged 65 and older, and those aged 12 through 64 years meeting certain criteria.
This affects the manufacturer of NUVAXOVID, regulatory affairs professionals managing vaccine portfolios, and clinical operations teams responsible for immunization protocols.
The source text establishes specific age-stratified criteria for the use of this protein-based vaccine. This indicates a nuanced regulatory approach where the indication for the 12-64 age group may be more restrictive or specific than for the 65+ demographic. Regulatory teams must ensure clinical site guidance and marketing materials align precisely with these age-based parameters to maintain compliance with the approved labeling.
Regulatory and clinical teams should update internal product monographs and labeling documentation to reflect the specific age-based indications. Documentation must differentiate between the primary 65+ demographic and the conditional 12-64 year demographic as specified in the approval text.
NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<br> <br> NUVAXOVID is approved for use in individuals who are:<br> <br> 65 years of age and older, or<br> <br> 12 years through 64 years of age with
Open in openFDA / FDA.gov